Page 13 - Aging Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eli Lilly drug shows significant results in slowing Alzheimer’s The experimental drug, donanemab, was studied at two R.I. hospitals By Alexa Gagosz Globe Staff,Updated March 15, 2021, 2:32 p.m. Email to a Friend Dr. Stephen Salloway is the director of the Memory and Aging Program at Butler Hospital, where he led the TRAILBLAZER study. He is also a professor of psychiatry and human behavior and of neurology at Brown University’s Warren Alpert Medical School.Nick Dentamaro/Brown University PROVIDENCE — Rhode Island is once again playing a critical role in the development of prom...

PROVIDENCE – A new investigational drug has demonstrated a significant reduction in cognitive deficits in people who are living in the early stages of Alzheimer’s disease, researchers at Butler and Rhode Island hospitals and Brown University have reported in the New England Journal of Medicine. The drug, donanemab, from pharmaceutical firm Eli Lilly and Company, targets the amyloid plaque and tau protein build-ups in the brain that are associated with the development of Alzheimer’s and other types of dementia. “This is yet another significant and encouraging milestone in what has pro...

A Tattoo on my Brain A Tattoo on my Brain A Tattoo on my Brain A Neurologist's Personal Battle against Alzheimer's Disease Search within full text Publisher: Cambridge University Press Print publication year: 2021 A Tattoo on my Brain Who would you like to send this to * Optional message Book description Dr Daniel Gibbs is one of 50 million people worldwide with an Alzheimer's disease diagnosis. Unlike most patients with Alzheimer's, however, Dr Gibbs worked as a neurologist for twenty-five years, caring for patients with the very disease now affecting him. Also unusual is that Dr Gibbs...

Dr. Stephen Salloway. Photo: Brown/CNE Butler Hospital in Providence announced on Monday that clinical trial results announced over the weekend and published in the New England Journal of Medicine (NEJM) indicate that the investigational drug donanemab holds promise as a potential treatment for early Alzheimer's disease.  Stephen Salloway, MD, MS, Director of the Memory and Aging Program and of Neurology at Butler Hospital and the Martin M. Zucker Professor of Psychiatry and Human Behavior and professor of Neurology at the Warren Alpert Medical School of Brown University, is a co-author of t...

by Naseem S. Miller, The Journalist's Resource February 23, 2021 h1 Covering the impact of COVID-19 on the LGBTQ community: 4 tips and 5 questions to get you started /h1 p class "byline" by Naseem S. Miller, The Journalist's Resource br February 23, 2021 /p p LGBTQ Americans are more likely than the general population to a href "https://williamsinstitute.law.ucla.edu/wp-content/uploads/COVID-LGBT-Fall-Surge-Feb-2102.pdf" target "_blank" rel "noreferrer noopener" live in poverty /a , a href "https://www.lgbtmap.org/2020-covid-lgbtq-households" target "_blank" rel "noreferrer noopener...